Leech bankrupt as ML Labs restructures

The FDA news was excellent for ML . Apart from the fact that this means that it will not have to repay Paul Capital some £5m it also means that additional royalties will be forthcoming from the US launch of Icodextrin . As a sideline ML retain the rights to the rest of the world , which must now be very valuable . Innovata Biomed is worth somewhere between £50 and £100m . Cobra is going great guns . Adept is another big earner in the future . The sum of parts is a large multiple of the current market cap and once the uncertainty over the large shareholding is taken away the share price will not look back . One thing for sure is that the large shareholding should not act a brake on the share price as it will not be sold into the market under any circumstances . An outstanding risk/reward situation .